PRME — Prime Medicine, Inc.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Market
- Employees: 214
- Website: https://www.primemedicine.com
Latest SEC filings for PRME
- 10-Q — 2026-08-06
- 8-K — 2026-08-06
- 8-K — 2026-07-08
- 8-K — 2026-06-08
- 8-K — 2026-05-07
- 10-Q — 2026-05-07
- ARS — 2026-04-23
- 8-K — 2026-04-16
- EFFECT — 2026-03-05
- 10-K — 2026-03-03
Latest PRME news
- — Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why (Zacks Investment Research)
- — Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why (zacks.com)
- — Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease (GlobeNewswire Inc.)
- — Prime Medicine Gets FDA Green Light for Gene Editing Study (benzinga.com)
- — Prime Medicine stock jumps 8% after FDA clears PM647 trial (seekingalpha_market)
Educational tool only — not investment advice.